Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alector, Inc.

Market Cap 174M 151M 139M 130M 243M 16.57B 247M 1.64B 639M 8.06B 654M 640M 27.92B P/E Ratio 2026 *
-1.83x
P/E Ratio 2027 * -2.45x
Enterprise Value -72.82M -62.9M -57.96M -54.25M -102M -6.92B -103M -684M -267M -3.37B -273M -267M -11.67B EV / Sales 2026 *
-10.6x
EV / Sales 2027 * -6.65x
Free-Float
87.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-2.55%
1 week-6.42%
Current month-29.17%
1 month-29.17%
3 months-31.39%
6 months+2.68%
Current year-1.92%
1 week 1.48
Extreme 1.485
1.74
1 month 1.48
Extreme 1.485
2.37
Current year 1.48
Extreme 1.485
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
43.32
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 70 2013-04-30
Director of Finance/CFO 53 2025-06-19
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap.
06-02Sell

Controller/Auditor

-3,475 0.0031%
06-01Sell

Chief Financial Officer

-19,360 0.0174%
06-01Sell

Founder

-87,216 0.0786%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-6.42%-5.56%-79.63% 174M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+2.79%-13.71%-17.53% 22.64B
+1.17%+3.85%+1.00%+401.79% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+0.82%+27.17%+178.31% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.36%-1.10%+25.44%+87.62% 21.01B
Weighted average by Cap. +1.70%+1.59%+33.69%+101.48%

Financials

2026 *2027 *
Net sales 6.86M 5.92M 5.46M 5.11M 9.57M 652M 9.72M 64.44M 25.12M 317M 25.73M 25.19M 1.1B 22.88M 19.76M 18.21M 17.05M 31.95M 2.17B 32.44M 215M 83.84M 1.06B 85.87M 84.05M 3.67B
Net income -94.11M -81.28M -74.9M -70.11M -131M -8.95B -133M -884M -345M -4.35B -353M -346M -15.08B -96.62M -83.45M -76.9M -71.98M -135M -9.18B -137M -908M -354M -4.47B -363M -355M -15.48B
Net Debt -247M -213M -197M -184M -345M -23.49B -350M -2.32B -906M -11.43B -927M -908M -39.59B -326M -282M -260M -243M -456M -31.02B -463M -3.07B -1.2B -15.1B -1.22B -1.2B -52.28B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-06-12 1.530 $ -2.55% 263,829
26-06-11 1.570 $ +3.29% 428,244
26-06-10 1.520 $ -6.75% 429,021
26-06-09 1.630 $ -0.61% 439,473
26-06-08 1.640 $ +0.31% 667,834
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.570USD
Average target price
3.100USD
Spread / Average Target
+97.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!